4 key facts about the new postpartum depression pill

Postpartum depression pill: An effective new treatment?

Many women suffer from postpartum depression.

Zuranolone could provide fast relief.

Postpartum depression is an issue that affects many women after giving birth.

A time that should be filled with joy and excitement for new mothers can sometimes become an enormous challenge.

However, the FDA has recently approved a pill for treating postpartum depression.

Find out more about this medication that was recently approved by the Food and Drug Administration.

What is postpartum depression?

PHOTO Shutterstock

Before addressing the topic of the postpartum depression pill, let’s learn more about this condition.Postpartum depression is a mental health issue that affects some women after giving birth. Although the postpartum period can be a time of joy and excitement, it can also be difficult.

Things like hormonal changes, emotional adjustments and physical challenges may predispose some women to develop it.

The FDA approves a postpartum depression pill

PHOTO Shutterstock

It’s also important to note that this condition is not a sign of weakness or an inability to be a good mother.

Rather, it is a complex reaction to biological, psychological and social factors.

Now, the Food and Drug Administration (FDA) has approved a postpartum depression pill.

According to infobae, more than 500,000 Americans suffer from this condition each year.

Zuranolone treats postpartum depression

PHOTO Shutterstock

According to the study, Zuranolone for the Treatment of Postpartum Depression, the pill relieves symptoms in as little as three days.

The study was published by The American Journal of Psychiatry.

The pill, called zuranolone, was specifically designed to treat postpartum depression.

According to infobae, zuranolone will be marketed in the United States under the brand Zurzuvae.

The review period

PHOTO Shutterstock

The postpartum depression pill was developed by a laboratory located in Massachusetts called Sage Therapeutics.

They produce zuranolone in partnership with Biogen, and it is expected to be available to the public soon.

This will happen after the FDA completes a 90-day review required for drugs that affect the nervous system.

Approval came on August 4th, and it is currently under FDA review to ensure its effectiveness.

Zurzuvae’s effectiveness

PHOTO Shutterstock

The New York Times has also reported on clinical trials of zuranolone.

They have noted that the pill works rapidly and is said to relieve postpartum depression in just three days.

This much faster than existing antidepressants.

Additionally, studies indicate that some women may only need to take the postpartum depression pill for two weeks, rather than months.

A 50% improvement in symptoms

PHOTO Shutterstock

In a recent trial, the efficacy and safety of a 50mg dose of zuranolone was studies, showing results on the third day.

According to infobae, after 14 days of treatment, researchers found that 57% of women reported a 50% improvement in symptoms.

This is compared to 38% of those who received a placebo instead.

After 45 days of treatment, 61.9% of those who received zuranolone reported a 50% or more improvement in their depressive symptoms.

The postpartum pill’s adverse effects

PHOTO Shutterstock

The study has also identified the most common adverse events with the use of zuranolone.

These include drowsiness, dizziness and sedation. However, no loss of consciousness was observed.

Nor were there any signs of withdrawal symptoms or an increase in suicidal ideation or behavior.

The conclusions point to the potential of zuranolone as a rapid-acting treatment for postpartum depression.